Stockscreener 앱 받기
89.70
0.38%
0.34
시간 외 거래:
91.30
1.60
+1.78%
전일 마감가:
$89.36
열려 있는:
$89.9
하루 거래량:
762.33K
Relative Volume:
1.03
시가총액:
$5.82B
수익:
$569.61M
순이익/손실:
$-23.36M
주가수익비율:
-6.5935
EPS:
-13.6043
순현금흐름:
$54.87M
1주 성능:
-2.32%
1개월 성능:
-8.54%
6개월 성능:
-0.52%
1년 성능:
+21.92%
1일 변동 폭
$88.28
$90.81
1주일 범위
$87.64
$94.57
52주 변동 폭
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
89.70 | 5.82B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharma wins FDA nod for Atebrioz - The Pharma Letter
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder - Seeking Alpha
MIRM5806400 Bond Profile: Coupon and Redemption - TradingView
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Business Wire
Mirum Pharmaceuticals wins Bay Area's 14th drug approval this year - The Business Journals
Why is Mirum Pharmaceuticals stock gaining today? By Investing.com - Investing.com Canada
US FDA approves Mirum's drug for rare bone disorder - Reuters
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31 - AD HOC NEWS
(MIRM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer - Contract Pharma
Mirum Pharmaceuticals stock pulls back as Bank of America reveals new stake and valuation stays belo - AD HOC NEWS
Mirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalysts - Moomoo
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events - Seeking Alpha
Mirum Pharmaceuticals at Morgan Stanley conference: growth meets key catalysts - Investing.com Canada
Mirum Pharmaceuticals Chief Financial Officer Sold Shares Worth Over $978K - TradingView
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - Stock Titan
Mirum Pharmaceuticals at H.C. Wainwright conference: growth, catalysts By Investing.com - Investing.com UK
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
MIRM: Commercial growth, pipeline catalysts, and global expansion position the business for continued momentum - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Citizens reiterates Mirum Pharmaceuticals stock rating at outperform By Investing.com - Investing.com Canada
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - investing.com
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - Stock Titan
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - Stock Titan
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):